Navigation Links
Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
Date:9/8/2008

WALTHAM, Mass., Sept. 8 /PRNewswire/ -- Logical Therapeutics, Inc., announced today the commencement of its double-blind, randomized, active-controlled, multinational study of LT-NS001, a novel prodrug, which is converted in the bloodstream to naproxen, a non-steroidal anti-inflammatory drug (NSAID). NSAIDs are the most common medications taken worldwide for the treatment of pain, inflammation, fever and arthritis, including both rheumatoid arthritis (RA) and osteoarthritis (OA).

"Despite a long history of successfully treating patients for pain and inflammation, NSAIDs have limitations that restrict their use. Gastrointestinal (GI) side effects are a significant safety problem," said Lutz Giebel, Chairman of Logical Therapeutics. Published studies have shown that NSAID use is responsible for 15-60% of hospital admissions for GI bleeding, amounting to approximately 100,000 hospitalizations and 10,000-20,000 deaths annually in the US. "A safer alternative would fulfill a significant unmet medical need," Dr. Giebel went on to say.

In pre-clinical studies in rats and dogs, LT-NS001 was shown to cause significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. The study will assess gastrointestinal injury by endoscopy after 7 days of therapy. LT-NS001 was previously evaluated in two Phase 1 randomized, placebo-controlled, single-dose and multiple-dose pharmacokinetic studies. In all cases, LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

The Company also announced the departure of founding CEO, Dr. Mitchell P. Fink, who resigned to pursue other interests.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are associate
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... Virtual Radiologic (vRad), a technology-enabled national radiology practice, ... solution, has been selected by Abbeville Area Medical ... South Carolina. AAMC selected vRad,s ... on-premise PACS that was developed by radiologists for ...
... NEW YORK, Nov. 29, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0693503/Medical-Devices---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics This ... from the following Asian countries: Azerbaijan, China, ...
Cached Medicine Technology:vRad Selected by Abbeville Area Medical Center for PACS Replacement 2vRad Selected by Abbeville Area Medical Center for PACS Replacement 3Medical Devices - Asia 2
(Date:7/12/2014)... July 13, 2014 Recently, Fadhits.com, a well-known ... of elegant long graduation dresses to its product ... for its loyal clients. It wants to bring more benefits ... are now offered at discounted prices, up to 72% off. ... is always working hard. Its online shop is a good ...
(Date:7/12/2014)... York, NY (PRWEB) July 12, 2014 ... steady growth over the past five years, buoyed by ... agricultural sector's supply management system. “Eggs are a relatively ... result, per capita egg consumption generally grows in line ... Industry Analyst Will McKitterick. Furthermore, demand for new specialty ...
(Date:7/12/2014)... July 12, 2014 Fresh off their respective ... will meet on September 5th at Sun Life Stadium ... to see some of the brightest stars in the world ... in Miami will be treated to some of the best ... currently ranked as the third best team in the world ...
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives ... Application & Geography – Trends & Forecast to 2018," ... forecasting of market volume and value. The report also ... The market of phthalic anhydride is projected to grow ... million by 2018, with a CAGR of 5.24% from ...
(Date:7/12/2014)... The "North American Interventional ... by Angioplasty Balloon (Plain/Old, Cutting), Stent ... Filter (Retrievable), Endovascular Stent Graft - ... the major market drivers, restraints, and ... , Browse 108 market data tables ...
Breaking Medicine News(10 mins):Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5
... , , ... cell volume measurement in the flexographic printing industry, will be ... is a highly versatile, lightweight instrument that is extremely accurate ... The MicroDynamics QC line of inspection microscopes have a reputation ...
... U.S. survey of Internet players finds , TUESDAY, Aug. ... not the stereotypical adolescent locked to a computer screen ... survey, are 35-year-old adults, many of whom are overweight, ... findings also show that the health consequences of video ...
... of Health have found that the activity of a protein ... brain cancer called glioblastoma multiforme (GBM). In a move toward ... block this activity and reduce the spreading of GBM cells ... form of brain cancer, with about half of patients expected ...
... specific protein on the surface of a common bacterial ... enter the brain, initiating the deadly infection known as ... improved vaccines to protect those most vulnerable, including young ... the Journal of Experimental Medicine . "Streptococcus ...
... /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com ... report that its clinical trial is currently being processed. The ... 60 days). The company expects the manufacturing license will be ... (referred to as "swine flu" early on) is a new ...
... , Hospitals, Physicians Work Together ... PRINCETON, N.J., Aug. 18 Twelve New Jersey hospitals and ... test an innovative new incentive method that aims to reduce healthcare ... The three-year trial program could serve as a basis to overhaul ...
Cached Medicine News:Health News:Video Gamers Older Than You Think 2Health News:Video Gamers Older Than You Think 3Health News:Video Gamers Older Than You Think 4Health News:NIH researchers identify key factor that stimulates brain cancer cells to spread 2Health News:NIH researchers identify key factor that stimulates brain cancer cells to spread 3Health News:How meningitis bacteria attack the brain 2Health News:How meningitis bacteria attack the brain 3Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 2Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4
... The AquaFlow™ Collagen Glaucoma Drainage Device ... sclerectomy procedure has been proven to ... both the complications often associated with ... for medications. As a result, patient ...
... Cruise Control is a ... as a filter between ... aspiration tubing that captures ... safety and efficiency of ...
... Xpress is an innovative, stat analyzer that ... with on-board co-oximetry and integrated data management ... tests include pH, PCO 2 , PO ... hemoglobin, sodium, potassium, chloride, ionized calcium, ionized ...
... last 25 years, Bio-logic has demonstrated continuous ... that introduced the first Digital EEG system ... to you! Ceegraph VISION is the first ... expanded to integrate all your EEG needs: ...
Medicine Products: